JP2024533485A5 - - Google Patents

Info

Publication number
JP2024533485A5
JP2024533485A5 JP2024516380A JP2024516380A JP2024533485A5 JP 2024533485 A5 JP2024533485 A5 JP 2024533485A5 JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024533485 A5 JP2024533485 A5 JP 2024533485A5
Authority
JP
Japan
Prior art keywords
sequence
cdr
self
ferritin
differs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/051361 external-priority patent/WO2023035084A1/en
Publication of JP2024533485A publication Critical patent/JP2024533485A/ja
Publication of JP2024533485A5 publication Critical patent/JP2024533485A5/ja
Pending legal-status Critical Current

Links

JP2024516380A 2021-09-13 2022-09-13 がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ Pending JP2024533485A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243372P 2021-09-13 2021-09-13
US63/243,372 2021-09-13
PCT/CA2022/051361 WO2023035084A1 (en) 2021-09-13 2022-09-13 Dr5-targeting multabodies for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024533485A JP2024533485A (ja) 2024-09-12
JP2024533485A5 true JP2024533485A5 (cg-RX-API-DMAC7.html) 2025-09-22

Family

ID=85507784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516380A Pending JP2024533485A (ja) 2021-09-13 2022-09-13 がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ

Country Status (9)

Country Link
US (1) US20240409652A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401790A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533485A (cg-RX-API-DMAC7.html)
KR (1) KR20240101550A9 (cg-RX-API-DMAC7.html)
CN (1) CN118317980A (cg-RX-API-DMAC7.html)
AU (1) AU2022344813A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231176A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003139A (cg-RX-API-DMAC7.html)
WO (1) WO2023035084A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020320459A1 (en) * 2019-08-01 2022-03-03 The Governing Council Of The University Of Toronto Multi-valent and multi-specific nanoparticle platforms and methods
WO2022109743A1 (en) * 2020-11-25 2022-06-02 The Hospital For Sick Children Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Similar Documents

Publication Publication Date Title
US12247074B2 (en) Antibody molecules
JP2021503455A5 (cg-RX-API-DMAC7.html)
JP2022544771A5 (cg-RX-API-DMAC7.html)
WO2019091436A1 (zh) 4-1bb抗体及其制备方法和应用
TW201930338A (zh) 抗ｃｄ３８抗體及其使用方法
JP2022535924A5 (cg-RX-API-DMAC7.html)
CN117143247A (zh) 双特异性蛋白质及其制备方法
NZ717476A (en) Anti-garp protein and uses thereof
JP2022512234A5 (cg-RX-API-DMAC7.html)
JP2018509901A (ja) Ｈｂｖ感染および関連症状を治療するための三重特異的結合分子
JP2018093875A5 (cg-RX-API-DMAC7.html)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2025063183A5 (cg-RX-API-DMAC7.html)
JP2026004299A5 (cg-RX-API-DMAC7.html)
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
CN112074541A (zh) Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
CN101189265B (zh) 抗il2抗体
JP2024532489A5 (cg-RX-API-DMAC7.html)
CN115397852A (zh) 工程化抗il-2抗体
JP2022538222A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
AR114436A1 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
JP2025541367A (ja) 多価および多重特異性サイトカインアンタゴニスト
WO2023125561A1 (zh) 靶向tigit的抗体和双特异性抗体及其应用